{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', '9.3.1 Adverse events', 'Adverse events reported by the patient or observed by the Investigator will be monitored, and', 'include:', 'Occurrence, seriousness, grade/intensity, relationship to study drug, resolution, and', 'outcome of serious adverse event (SAE), adverse event of special interest (AESI) , and', 'AEs.', 'Assessment of IARs: An IAR is defined as any AE occurring during alemtuzumab', 'infusion or within the 24 hour post-infusion period. However, some IARs may occur', 'beyond 24 hours (such as pulmonary alveolar hemorrhage, stroke, cervicocephalic arterial', 'dissection, myocardial ischemia, thrombocytopenia and myocardial infarction). Toxicity', 'grade (severity) of IAR is based on CTCAE. The timing of IAR in relation to', 'alemtuzumab administration and distribution of IARs based on toxicity grade (severity)', 'observed in the study for both study periods will be assessed.', 'Refer to Section 10.4.1 for details.', '9.3.2 Laboratory safety variables', 'The clinical laboratory data consist of blood analysis (including hematology, clinical chemistry,', 'and urinalysis). Clinical laboratory values will be analyzed after conversion into standard', 'international units. International units will be used in all listings and tables.', 'All laboratory data listed in this section will be measured at a central laboratory. The laboratory', 'data will be collected at designated visits as shown in study flow chart Section 1.2.', 'It is preferred that CBCs with platelet count (for monitoring for any cytopenia as well as), serum', 'creatinine, and urinalysis with microscopy be analyzed at the central laboratory, but under special', 'circumstances (eg, if patient is unable to visit the study center weekly or monthly, or results are', 'needed urgently), the assay may be performed at a local laboratory provided that test results are', 'entered into the e-CRF in a timely manner. In addition, at some visits during the safety monitoring', 'phase, there is an option for the nurse to obtain samples for clinical chemistry laboratories,', \"hematology, thyroid function tests, urinalysis and serum creatinine at the patient's home if needed\", '(refer to study flow chart Section 1.2).', 'The following laboratory safety variables will be analyzed:', 'Hematology and differential panel: red blood cell count, hematocrit, hemoglobin, mean', 'corpuscular hemoglobin, white blood cell count with differential count (neutrophils,', 'eosinophils, basophils, monocytes, and lymphocytes) and platelets.', 'Complete Chemistry panel: glucose, serum creatinine, blood urea nitrogen (BUN),', 'sodium, potassium, chloride, bicarbonate, magnesium, calcium, uric acid, aspartate', 'aminotransferase, alanine aminotransferase (ALT), gamma-glutamyl transferase, lactate', 'dehydrogenase, total bilirubin, direct/indirect bilirubin, alkaline phosphatase, inorganic', 'phosphorus, total protein, albumin, globulin, albumin/globulin ratio, triglycerides, total', 'cholesterol and creatinine phosphokinase.', 'Property of the Sanofi Group - strictly confidential', 'Page 59', 'VV-CLIN-02544065 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'Urinanalysis: pH, ketones, protein, glucose, blood, urobilinogen, bilirubin, microscopic', 'sediment, specific gravity.', 'Thyroid function testing: thyroid stimulating hormone and if abnormal T3 and T4.', 'Hepatitis B and C serology testing.', 'HPV serology testing: Testing will be conducted for human papillomavirus (HPV)', 'infection as and when recommended by local public health authorities. If the testing is', 'positive, the patient may be eligible after the condition has resolved as per the Investigator', 'opinion (eg, follow-up HPV test is negative or cervical abnormality has been effectively', 'treated). An annual follow-up is recommended.', 'Tuberculosis test screening. It should be performed as per local health care authority', 'recommendations.', 'Pregnancy testing: \u00df-Human chorionic gonadotropin.', 'In accordance with international recommendations (20), sampling blood volume will be', 'minimized to approximately 1% of total blood volume at each visit and approximately 3% of total', 'blood volume over a 4 week period.', 'Blood sample volume will range from 9 to 57 ml, depending on tests required at study visits', '(ie, an average blood sample amount of 23 ml per visit). The total amount of blood withdrawn', 'will be approximately 350 ml in Year 1 and 200 ml in Year 2. During the safety monitoring phase,', 'approximately 120 ml will be drawn each year. However, additional blood samples may be', \"collected at the Investigator's discretion for patient safety monitoring.\", '9.3.3 ITP, cytopenia, and antiGBM surveillance and monitoring', 'In an effort to identify ITP early and minimize the risk of bleeding due to low platelet counts, this', 'protocol requires safety measures including monthly blood testing to monitor CBCs with platelet', 'count for monitoring for any cytopenia. Patients with certain abnormalities may be required to', 'have more frequent blood tests. See Appendix B (Immune thrombocytopenia).', 'If a cytopenia is suspected, appropriate medical intervention should be promptly initiated,', 'including referral to specialist.', 'Alemtuzumab has also been associated with antiGBM disease, which can cause a pulmonaryrenal', \"syndrome known as Goodpasture's disease (21, 22). AntiGBM disease is a rare autoimmune\", 'disorder in which circulating antibodies are directed against an antigen normally present in the', 'basement membranes of renal glomeruli and pulmonary alveoli. The target antigen is the alpha-3', 'chain of type IV collagen. The resultant clinical syndrome encompasses a spectrum ranging from', 'mild or no renal involvement to rapidly progressive glomerulonephritis. Patients may develop', 'pulmonary hemorrhage.', 'In an effort to identify potential cases of antiGBM disease early, all patients in the study will', 'undergo monthly evaluation of serum creatinine levels alone or as part of a full chemistry panel', 'and laboratory urinalysis (minimally including examination of protein and hemoglobin) with', 'Property of the Sanofi Group - strictly confidential', 'Page 60', 'VV-CLIN-02544065 5.0']\n\n###\n\n", "completion": "END"}